PPT-A Comparison of Angiotensin Receptor-Neprilysin Inhibition

Author : pasty-toler | Published Date : 2016-06-13

Milton Packer John JV McMurray Akshay S Desai Jianjian Gong Martin P Lefkowitz Adel R Rizkala Jean L Rouleau Victor C Shi Scott D Solomon Karl Swedberg and Michael

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "A Comparison of Angiotensin Receptor-Nep..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

A Comparison of Angiotensin Receptor-Neprilysin Inhibition: Transcript


Milton Packer John JV McMurray Akshay S Desai Jianjian Gong Martin P Lefkowitz Adel R Rizkala Jean L Rouleau Victor C Shi Scott D Solomon Karl Swedberg and Michael R Zile for the PARADIGMHF Investigators and Committees. Inhibition is a term used to describe the inability of a product being formed due to the presence of another substance (the inhibitor). Enzyme inhibition . can be competitive or noncompetitive. Competitive inhibition is caused when an inhibitor “competes” with the substrate in binding with the enzyme. Pratt & . Cornely. . Ch. 7. Enzyme Kinetics. How fast an enzyme catalyzed reaction goes. Why study enzyme kinetics?. Helps us understand mechanism of enzyme (how it works). Investigation of mutations in metabolic pathways. The structure of a noncompetitive inhibitor does not resemble the substrate and does not compete for the active site. .. Learning Goal . . Describe competitive and . noncompetitive inhibition . and reversible and irreversible inhibition. Shannon Harris, DNP, FNP. Objectives. Causes of hypertension. Classifications of hypertension. Risk factors. Diagnosis . Complications. Management . Final thoughts. Hypertension. The #1 modifiable risk factor for stroke. Kelsey Davis, Courtney Getchell, Robert . Kolar. Introduction. We will be covering the topic of . prodrugs. , specifically a hypertension medication . Olmesartan. .. An introduction to . prodrugs. and what they are used for.. MARLON T. CO,MD. DISCLOSURE. Advisory board of Merck Philippines. Ps-DZ, 2009. Global Leading Risks for Death, 2010. Systolic blood pressure > 115 mmHg. Global Burden of Disease Study 2010 , . Lancet . COMPARISON OF ADJECTIVES DEGREES OF COMPARISON DEGREES OF COMPARISON COMPARATIVE DEGREE (Grau Comparativo) Compara UM elemento com OUTRO . Nessa comparação poderá haver IGUALDADE, DESIGUALDADE, SUPERIORIDADE Blockers. :. Impact on Adverse Outcomes in Hospitalized Patients . with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2). THE BRACE CORONA TRIAL. Renato D. Lopes, MD, PhD. on behalf of the BRACE CORONA Investigators. enzyme inhibitors (ACE inhibitors). inhibit the conversion of angiotensin I to angiotensin II.. The. . main . indications of ACE inhibitors are shown below.. Heart Failure. ACE inhibitors are used in all grades of heart failure, . W. Hinton. 1,2. , H. Dambha-Miller. 3. , M.Feher. 1. , J. Sheppard. 1. , M.Joy. 1. , N. Munro. 2,4. , . S. de Lusignan. 1,5. 1 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. McCann CM, Vyse AJ, Salmon R, Thomas D, Williams DJ, McGarry JW, et al. Lack of Serologic Evidence of Neospora caninum in Humans, England. Emerg Infect Dis. 2008;14(6):978-980. https://doi.org/10.3201/eid1406.071128. AMVAC Chemical Corporation. FMC Corporation. Gowan. Company. September 15-18, 2020. Outline of Presentation. Introduction to Testing Program (Rick Reiss) – 15 minutes. Experimental Procedures and Results (Jan Chambers) – 20 minutes. Dr. Sara . Assadiasl. MD.PhD. . of immunology. Assistant professor. Molecular immunology research center. Tehran university of medical sciences. Immunosuppression. T cell inhibition. B cell inhibition. BP. Congest-ion*. Haemo. -globin. K. +. GFR. BNP#. Echo. Diuretics. . . . . . . . ACEi/ARB. . . . I. ARNI. . . . I. I. β. -Blocker. R?. . R?. . I. MRA. .

Download Document

Here is the link to download the presentation.
"A Comparison of Angiotensin Receptor-Neprilysin Inhibition"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents